IDH-1

Identifies isocitrate dehydrogenase 1, an enzyme that participates in the citric acid cycle and is mutated in a high fraction of gliomas and oligodendrogliomas, particularly in grade II and grade III neoplasms. These mutations are frequent genetic alterations in low-grade diffuse gliomas and secondary glioblastoma (70%), and has been observed in fewer than 10% of primary glioblastoma cases. The antibody is a diagnostic tool in assessing the mutational status of codon 132 (R132H) and does not cross react with the native protein, helping differentiate GBM tumors from others. Because these mutations do not occur in reactive gliosis, these can often be separated from diffuse gliomas, which are usually positive for the mutation.